Albidon
REDUCEAfrica-focused mineral explorer and developer Albidon has followed confirmation of high-grade zinc at Nefza in Tunisia with encouraging drilling results from its Njame uranium prospect in Zambia.
Based in Western Australia and quoted on AIM, the company says Njame assays include 17 metres at 835 parts per million of U308, 13 metres at 587 parts per million and six metres at 602 parts per million. Albidon, at which Placer Dome Asia Pacific veteran John Shaw replaces Dick Potts as chairman in May, says it hopes to finish a pre-feasibility study on Njame and another deposit, Gwabe, in the Chirundu joint venture in Zambia by April and aims to produce a formal resource estimate for Njame in the second quarter of this year.
Last month, the company, also involved in the Munali nickel joint venture in Zambia, said initial drilling in Tunisia at Khatkhadha in the Bou Aouane district of the Nefza project had intersected 8.1 metres with 11.7 per cent zinc. According to Albidon, a second hole to the south-east of Khatkhada showed 21.4 metres with 2.4 per cent zinc and 1.7 per cent lead.
Shares in cash-hungry Albidon, which recently raised £5 million from Munali partner ZCCM and another £8 million at 165p from Chinese mining group Jinchuan, have risen from 37p, at which Growth Company Investor recommended them in 2006, to 165.5p today, 6.5p off yesterday’s 172p peak.
Partial profit-taking looks prudent.
Growth Company Investor is the UK’s leading authority on small-cap and AIM companies. You can gain immediate access to all the recent share recommendations with no obligation, with a free 30-day trial. Click here to join today.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £266.2m
PE Forecast: n/a
Share price: 165.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
